Head to head
OrthoPediatrics vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: KIDS · ABT
KIDS
OrthoPediatrics
21.92-2.48%
1-year price shape — +24% over the period
Quant Rating B · 71/100
vs
ABT
Abbott Laboratories
97.43-1.32%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| KIDS | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 21.92 | 97.43 |
| Change today | -2.48% | -1.32% |
| 1-year return | +24.3% | -24.1% |
| Market cap | $572.39M | $168.58B |
| 52-week range | 14.42 – 26.74 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -13.05 | 31.53 |
| P/E percentile, own 5-yr range | 52nd | 62nd |
| P/B | 1.67 | 3.30 |
| Dividend yield | 0.00% | 2.50% |
| Profitability & growth | ||
| EPS (TTM) | -1.69 | 3.72 |
| Net profit (TTM) | $-44.13M | $6.44B |
| Revenue (TTM) | $252.73M | $46.59B |
| Revenue growth (YoY) | +15.4% | +13.0% |
| Gross margin | 73.7% | 56.6% |
| Operating margin | -9.0% | 15.8% |
| Net margin | -15.7% | 11.6% |
| Free cash flow (TTM) | $-1.84M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 90.3% | 81.2% |
| Insider activity (12mo) | 31 buy / 18 sell | 36 buy / 12 sell |
| Short interest (% of float) | 3.4% | 1.1% |
| Analyst consensus | 88% buy / 12% hold (8) | 100% buy (14) |
| Analyst price target | $28 (+25%) | $125 (+28%) |
| StockVane view | ||
| StockVane Quant Rating | B (71) | E (15) |
| Company | ||
| Employees | 602 | 115,000 |
| Founded | 2006 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.